<DOC>
	<DOCNO>NCT01472770</DOCNO>
	<brief_summary>The present study aim investigate efficacy safety combination capecitabine gemcitabine heavily pre-treated , treatment resistant metastatic colorectal cancer .</brief_summary>
	<brief_title>A Phase II Study Gemcitabine Capecitabine Treatment Resistant , Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically verify colorectal adenocarcinomas Age &gt; 18 year Metastatic colorectal cancer refractory 5FU , oxaliplatin , irinotecan relevant biological agent . Measurable disease accord RECIST 1.1 ECOG performance status 0 , 1 2 Adequate renal , hepatic haematological function Consent blood sample available paraffin embed tumour material translational research study Fertile male female ( &lt; 2 year last period woman ) must use effective birth control . Signed Informed consent Clinically significant concurrent disease . Other malignant disease within 5 year inclusion study , except squamous cell carcinoma skin cervical carcinomainsitu . Other experimental therapy within 30 day treatment initiation . Patients breast feeding , childbearing childbearing potential without use dual effective contraception . Clinical radiological evidence CNS metastasis . Planned radiation therapy targetlesions . Known allergy 5FU/capecitabine gemcitabine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Treatment resistant</keyword>
</DOC>